A phase II study of first-line erlotinib in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC) including dose escalation to toxicity in current and former …
8111 Background: Skin rash has been associated with increased activity of erlotinib in
retrospective analyses and plasma levels of erlotinib are lower in current vs former or non …
retrospective analyses and plasma levels of erlotinib are lower in current vs former or non …
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2
R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
S Ricciardi, S Tomao, F de Marinis - Lung Cancer: Targets and …, 2010 - Taylor & Francis
Lung cancer is the leading cause of cancer deaths worldwide. Targeting the epidermal
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
growth factor receptor (EGFR) has played a central role in advancing non-small-cell lung …
Clinical study on the efficacy and safety of erlotinib in treatment of advanced non-small cell lung cancer
SW ZHOU - Tumor, 2008 - pesquisa.bvsalud.org
Objective: To investigate the efficacy and adverse reaction of erlotinib as a single agent in
2nd and 3rd treatment of advanced non-small cell lung cancer (NSCLC) patients. Methods …
2nd and 3rd treatment of advanced non-small cell lung cancer (NSCLC) patients. Methods …
Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non–small-cell lung cancer: A meta-analysis based on randomized …
H Deng, L Wang, X Chen, S Zhang, F Yi, Y Wei… - Medicine, 2020 - journals.lww.com
Background: Whether erlotinib plus tivantinib (ET) can achieve better clinical benefits than
erlotinib plus placebo (EP) among participants with previously treated advanced non-small …
erlotinib plus placebo (EP) among participants with previously treated advanced non-small …
A randomized phase II study comparing erlotinib (E) versus E alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. The NVALT10 …
JG Aerts, H Codrington, S Burgers… - Annals of …, 2012 - annalsofoncology.org
Introduction Epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) administered
concurrently with chemotherapy did not improve outcome. However, in preclinical models …
concurrently with chemotherapy did not improve outcome. However, in preclinical models …
Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC
W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2009 - ascopubs.org
8020 Background: The SATURN (BO18192) study investigated whether erlotinib
maintenance therapy improved PFS in patients (pts) with advanced NSCLC who had …
maintenance therapy improved PFS in patients (pts) with advanced NSCLC who had …
Efficacy and safety of erlotinib in the treatment for advanced non-small cell lung cancer in Chinese patients
YL Wu, ML Liao, SK Qin, Y Sun… - Zhonghua Zhong liu za zhi …, 2010 - europepmc.org
Objective To observe the efficacy and the adverse effects of erlotinib in the treatment for
advanced non-small cell lung cancer (NSCLC) in Chinese patients. Methods From …
advanced non-small cell lung cancer (NSCLC) in Chinese patients. Methods From …
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clinical Cancer …, 2005 - AACR
Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …